Dermal absorption and toxicity of alpha amanitin in mice

Ertugrul Kaya1, Mustafa Gani Surmen, Kursat Oguz Yaykasli

  • 1Department of Medical Pharmacology and.

Insights

Alpha amanitin, a toxin from Amanita phalloides, showed no toxicity when applied percutaneously to mice. This suggests alpha amanitin may be safely administered topically for therapeutic uses.

Area of Science:

  • Toxicology
  • Pharmacology
  • Mycology

Background:

  • Amanita phalloides contains amanitins and phallotoxins.
  • Alpha amanitin inhibits eukaryotic RNA polymerase II.
  • Potential therapeutic applications for alpha amanitin exist, particularly as an antiparasitic or antifungal agent.

Purpose of the Study:

  • To compare the toxicity and absorption of percutaneous versus intraperitoneal (ip) alpha amanitin administration in mice.
  • To evaluate potential skin, liver, and kidney toxicity following alpha amanitin exposure.
  • To determine the feasibility of percutaneous alpha amanitin application for therapeutic purposes.

Main Methods:

  • Mice received 1 mg/kg of alpha amanitin via percutaneous or ip routes.
  • Pathological examination assessed skin, liver, and kidney toxicity.
  • High-performance liquid chromatography (HPLC) quantified toxin levels.

Main Results:

  • No toxicity or detectable alpha amanitin was found in the skin, liver, or kidneys of the control or percutaneous application groups.
  • Intraperitoneal administration led to observable toxicity, including Councilman-like bodies and pyknotic cells, within 24 hours.
  • Peak alpha amanitin levels in the ip group were measured in the liver (3.3 µg/mL at 6h), blood (1.2 µg/mL at 1h), and kidney (0.2 µg/mL at 6h).

Conclusions:

  • Percutaneous application of alpha amanitin in mice resulted in no systemic absorption or toxicity.
  • Intraperitoneal administration of alpha amanitin demonstrated significant toxicity.
  • Alpha amanitin is a potential candidate for percutaneous therapeutic administration due to its lack of skin absorption and toxicity.